SCHEMBL7066334

SCHEMBL7066334

CC(C)CC(NS(=O)(=O)c1cccc2c(N(C)C)cccc12)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TYMS P04818 4/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP2C19 P33261 1/20 0.52
F2 P00734 2/20 0.52
EDNRA P25101 1/20 0.51
PRSS1 P07477 1/20 0.50
PRSS2 P07478 1/20 0.50
PRSS3 P35030 1/20 0.50
KDM4E B2RXH2 1/20 0.49
GLB1 P16278 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805481 1.00 TYMS (0.52) TYMSALDH1A1CYP2C19F2EDNRA
SCHEMBL3813102 1.00 TYMS (0.52) TYMSALDH1A1CYP2C19F2EDNRA
SCHEMBL5706271 0.88 TYMS (0.54) TYMSCYP2C19F2EDNRAPRSS1
SCHEMBL6266410 0.88 TYMS (0.54) TYMSF2EDNRAPRSS1PRSS2
SCHEMBL8842854 0.87 TYMS (0.53) TYMSF2EDNRAPRSS1PRSS2
SCHEMBL13066809 0.87 TYMS (0.53) TYMSF2EDNRAPRSS1PRSS2
SCHEMBL180018 0.87 TYMS (0.53) TYMSF2EDNRAPRSS1PRSS2
SCHEMBL180019 0.87 TYMS (0.53) TYMSF2EDNRAPRSS1PRSS2
SCHEMBL13884437 0.87 TYMS (0.53) TYMSF2EDNRAPRSS1PRSS2
SCHEMBL179968 0.86 TYMS (0.52) TYMSCYP2C19F2EDNRAPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180282530-A1 APPLICATION OF CYCLODEXTRINS (CDS) FOR REMEDIATION OF PERFLUOROALKYL SUBSTANCES (PFASS) THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2018-10-04 US claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP claimed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO claimed
CN-119174932-A Preparation method of capillary chromatographic column based on metal organic framework material and used for chiral separation 上海大学 2024-12-24 CN disclosed
US-12043732-B2 Application of cyclodextrins (CDs) for remediation of perfluoroalkyl substances (PFASs) THE FLORIDA INTERNATIONAL UNIVERISITY BOARD OF TRUSTEES (US) 2024-07-23 US disclosed
US-20220023332-A1 Application of Cyclodextrins (CDs) for Remediation of Perfluoroalkyl Substances (PFASs) THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2022-01-27 US disclosed
US-11149135-B2 Application of cyclodextrins (CDS) for remediation of perfluoroalkyl substances (PFASS) THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2021-10-19 US disclosed
CN-111001187-B Preparation method of novel cyclodextrin metal organic framework material chiral capillary electrochromatography open tubular column 武汉大学 2021-02-19 CN disclosed
CN-111001187-A Preparation method of novel cyclodextrin metal organic framework material chiral capillary electrochromatography open tubular column 武汉大学 2020-04-14 CN disclosed
US-20180282530-A1 APPLICATION OF CYCLODEXTRINS (CDS) FOR REMEDIATION OF PERFLUOROALKYL SUBSTANCES (PFASS) THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2018-10-04 US disclosed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6528642-B1 ALKENYLATED CYCLODEXTRIN COMPOUNDS AND POLYMERS MADE TTHEREOF ; MADE BY REACTING AN ALKENYL HALIDE WITH CYCLODEXTRIN; USE AS SUPPORT FOR SEPARATION OF ENANTIOMERS, OTHER ISOMERS, AND HYDROPHOBIC ORGANIC MOLECULES, OR AS CATALYST SUPPORT INSTITUT FRANCAIS DU PETROLE (FR) 2003-03-04 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 TYMS 1396/4885ALDH1A1 3364/4885CYP2C19 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.